AQST — Aquestive Therapeutics Share News
0.000.00%
Last trade - 00:00- $507.07m
- $549.32m
- $44.55m
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Aquestive rises on US licensing deal for seizure drug with Eton Pharma
Aquestive Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aquestive Therapeutics Q2 revenue beats on Suboxone strength
Brief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million
Brief: Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt As Chief Medical Officer
Brief: Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For Anaphylm
NASDAQ RESUMED AT 07:30 AM
US FDA declines to approve Aquestive's oral drug for allergic reactions (updated)
US FDA declines to approve Aquestive's oral drug for allergic reactions
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
U.S. STOCKS ON THE MOVE-Intel, Gartner, Chipotle
U.S. STOCKS ON THE MOVE-Spotify, Insmed, Nano Nuclear Energy